Literature DB >> 18186545

Experimental design and interaction analysis of combination studies of drugs with log-linear dose responses.

Hong-Bin Fang1, Douglas D Ross, Edward Sausville, Ming Tan.   

Abstract

Drug combination is a major treatment approach in cancer and antiviral therapies. A key issue is to find which combinations are additive, synergistic or antagonistic. In this paper, we develop statistical methods for experimental design and data analysis of combination studies of drugs that have log-linear dose-response curves. This class of dose response includes the Hill, sigmoid and simple exponential models. The experimental design (dose-finding and sample size determination) is derived by means of uniform measures that maximize the minimum power of the F-test to detect any departures from additive action and at the same time minimizes the maximum bias due to lack of fit among all potential departures of a given meaningful magnitude. Furthermore, we propose a model-free interaction index surface to capture the interaction of two drugs. The nonparametric function of the interaction index is estimated using the technique developed in thin plate splines. These methods are applicable to both in vivo and in vitro experiments. A study of two anticancer drugs, suberoylanilide hydroxamic acid (Vorinostat) and Etoposide applied sequentially against the cell line HL-60, is given to illustrate the proposed methods of experimental design and interaction analysis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18186545     DOI: 10.1002/sim.3204

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  8 in total

1.  The novel BCR-ABL and FLT3 inhibitor ponatinib is a potent inhibitor of the MDR-associated ATP-binding cassette transporter ABCG2.

Authors:  Rupashree Sen; Karthika Natarajan; Jasjeet Bhullar; Suneet Shukla; Hong-Bin Fang; Ling Cai; Zhe-Sheng Chen; Suresh V Ambudkar; Maria R Baer
Journal:  Mol Cancer Ther       Date:  2012-07-09       Impact factor: 6.261

2.  Synergistic inhibition of glioma cell proliferation by Withaferin A and tumor treating fields.

Authors:  Edwin Chang; Christoph Pohling; Nooshin Beygui; Chirag B Patel; Jarrett Rosenberg; Dong Ho Ha; Sanjiv S Gambhir
Journal:  J Neurooncol       Date:  2017-07-05       Impact factor: 4.130

3.  Nonlinear response surface in the study of interaction analysis of three combination drugs.

Authors:  Wen Wan; Xin-Yan Pei; Steven Grant; Jeffrey B Birch; Jessica Felthousen; Yun Dai; Hong-Bin Fang; Ming Tan; Shumei Sun
Journal:  Biom J       Date:  2016-05-17       Impact factor: 2.207

4.  An application of a Hill-based response surface model for a drug combination experiment on lung cancer.

Authors:  Shaoyang Ning; Hongquan Xu; Ibrahim Al-Shyoukh; Jiaying Feng; Ren Sun
Journal:  Stat Med       Date:  2014-06-18       Impact factor: 2.373

5.  Experimental design for multi-drug combination studies using signaling networks.

Authors:  Hengzhen Huang; Hong-Bin Fang; Ming T Tan
Journal:  Biometrics       Date:  2017-09-28       Impact factor: 2.571

6.  Salvianolic Acid B and Ginsenoside Re Synergistically Protect Against Ox-LDL-Induced Endothelial Apoptosis Through the Antioxidative and Antiinflammatory Mechanisms.

Authors:  Ke Yang; Yun Luo; Shan Lu; Ruifeng Hu; Yuyang Du; Ping Liao; Guibo Sun; Xiaobo Sun
Journal:  Front Pharmacol       Date:  2018-06-20       Impact factor: 5.810

Review 7.  Risk assessment of toxins derived from Bacillus thuringiensis-synergism, efficacy, and selectivity.

Authors:  Christoph Then
Journal:  Environ Sci Pollut Res Int       Date:  2009-06-26       Impact factor: 4.223

Review 8.  Advances in Synergistic Combinations of Chinese Herbal Medicine for the Treatment of Cancer.

Authors:  Xue-Qing Hu; Yang Sun; Eric Lau; Ming Zhao; Shi-Bing Su
Journal:  Curr Cancer Drug Targets       Date:  2016       Impact factor: 3.428

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.